Market news

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massach

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026: Cantor Global Healthcare Conference: Fireside chat on Wednesday, September 9, 2026 at 2:45 p.m. ET H.C. Wainwright 28th Annual Global Inves

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants i

Tipranks Press Release.